EUCTR2016-002763-34-ES进行中（未招募）1 期
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Must have the ability to understand and sign a written ICF, which must be obtained prior to initiation of study procedures associated with this trial
- •Must have met all eligibility criteria from a Gilead-sponsored CD parent
- •Females of childbearing potential must have a negative pregnancy test at Day 1 and must agree to continued monthly pregnancy testing during use of filgotinib treatment
- •Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
- •Willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 920
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •Subjects who are discontinued from a parent study for reasons other than disease worsening, or lack of response or remission; eg, subjects who discontinue for safety or tolerability issues are not eligible for the present study.
- •Known hypersensitivity to the study drug
- •Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the Investigator, would make the subject unsuitable for the study or would prevent compliance with the study protocol
- •Females who may wish to become pregnant and/or plan to undergo egg donation or egg harvesting for the purpose of current or future fertilization during the course of the study and for at least 35 days of the last dose of the study drug
- •Male subjects unwilling to refrain from sperm donation for at least 90 days after the last dose of study drug
- •Males or females of reproductive potential who are unwilling to abide by protocol-specified contraceptive methods as defined in the protocol
- •Use of prohibited medications as outlined in the protocol
研究者
相似试验
进行中（未招募）
1 期
A Long Term Study to Follow the Safety of a New Treatment in Patients with Crohn’s DiseaseEUCTR2016-002763-34-ISGilead Sciences, Inc.1,000
进行中（未招募）
1 期
A Long Term Study to Follow the Safety of a New Treatment in Patients with Ulcerative Colitislcerative Colitis (UC)MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2016-002765-58-NLGalapagos NV1,000
进行中（未招募）
1 期
A Long Term Study to Follow the Safety of a New Treatment in Patients with Ulcerative ColitisEUCTR2016-002765-58-BGGilead Sciences, Inc.1,000
进行中（未招募）
1 期
A Long Term Study to Follow the Safety of a New Treatment in Patients with Crohn’s DiseaseModerately to Severely Active Crohn's Disease (CD)MedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856EUCTR2016-002763-34-ATGalapagos NV1,000
进行中（未招募）
1 期
A Long Term Study to Follow the Safety of a New Treatment in Patients with Crohn's DiseaseModerately to Severely Active Crohn's Disease (CD)MedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856EUCTR2016-002763-34-ITGILEAD SCIENCES INCORPORATED1,000